The Bristol-Myers Squibb-Pfizer Alliance will present 15 Eliquis® (apixaban) posters at the ESC Congress 2018 held in Munich, Germany, August 25-29, 2018. Nine of the posters to be presented are new analyses from the global real-world data (RWD) program, ACROPOLIS™ (Apixaban ExperienCe Through Real-WOrld POpuLatIon Studies), exploring the effectiveness and safety of anticoagulants, including Eliquis, among patients with non-valvular atrial fibrillation.

Ziylo and Novo Nordisk A/S today announced that Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. Ziylo has been pioneering the use of its platform technology - synthetic glucose binding molecules - for therapeutic and diagnostic applications.

Merck, the vibrant science and technology company, today announced that the Australian Patent Office has allowed the company's patent application for the use of paired CRISPR nickases. Paired nickases represent a significant step in increasing safety by driving specificity through a highly flexible and efficient approach to reduce off-target effects.

AstraZeneca and Merck & Co., Inc., Kenilworth, NJ, US (known as MSD outside the US and Canada) announced that the European Medicines Agency (EMA) has granted orphan designation to selumetinib, a MEK 1/2 inhibitor, for the treatment of neurofibromatosis type 1 (NF1).

Boehringer Ingelheim, the UK Cystic Fibrosis Gene Therapy Consortium (GTC) - consisting of Imperial College London and the Universities of Oxford and Edinburgh - Imperial Innovations, and Oxford BioMedica (OXB) announce a global collaboration to develop a first-in-class, long-term therapy for patients with cystic fibrosis (CF).

Grants4Impact (G4I), a new energizer program launched by Bayer Cares Foundation, is providing targeted support to social impact pioneers and start-ups in the fields of healthcare and nutrition. The aim of the program is to give selected change-makers around the world new opportunities to grow and transform great ideas into powerful impact solutions that help to improve the lives of millions.

Amgen (NASDAQ:AMGN) today announced the groundbreaking of its new next-generation biomanufacturing plant that will be constructed at its West Greenwich, R.I. campus. The new plant is the first-of-its-kind in the U.S. and will use Amgen's proven next-generation biomanufacturing capabilities to manufacture products for the U.S. and global markets.